Furthermore, 14 genes were identified as potential prognostic markers associated with Th1 and Th2 responses and major inflammatory signaling pathways, including NF-κB and IL-6/STAT3 signaling: SLC11A1, TNFRSF1B, and LTBR were found to be especially promising predictors of the prognoses of GBM patients and could be used to develop effective GBM treatment strategies. This evidence concerns the gene SLC11A1 and glioblastoma.